AIM ImmunoTech Inc (AIM)

AIM ImmunoTech Inc (AIM) is a Biotechnology company in the Healthcare sector listed on the AMEX.

As of Oct 23, 2026: market cap $6.7M; returns 1 day -2.9%, 1 week -7.0%, 1 year -93.9%.

AIM ImmunoTech Inc. is a clinical-stage immuno-pharma company primarily engaged in the research and development of novel therapeutics for various cancers, immune disorders, and viral diseases. The company's lead product candidate is Ampligen® (rintatolimod), a proprietary double-stranded RNA (dsRNA) molecule that acts as a highly selective Toll-like Receptor 3 (TLR3) agonist.

Groups AIM belongs to

• Clinical Stage Biotech
• Biotechnology
• Biopharmaceutical
• Immunotherapy
• Clinical Stage
• Oncology
• Cancer Therapeutics
• Infectious Diseases
• Antivirals

AIM financial model: income statement, cash flow and balance sheet